Comment on Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. [J Clin Oncol. 2017]
Bevacizumab in small cell lung cancer
Roviello, Giandomenico;Sobhani, Navid;Generali, Daniele
2017-01-01
Abstract
Comment on Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. [J Clin Oncol. 2017]File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Roviello G Bevacizumab in SCLC.pdf
accesso aperto
Tipologia:
Documento in Versione Editoriale
Licenza:
Creative commons
Dimensione
107.57 kB
Formato
Adobe PDF
|
107.57 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
